Ovarian cancer is the leading cause of gynecological cancer-related mortality globally. The majority of ovarian cancer patients suffer from relapse after standard of care therapies and the clinical benefits from cancer therapies are not satisfactory owing to drug resistance. Certain novel drugs targeting the components of tumor microenvironment (TME) have been approved by US Food and Drug Administration in solid cancers. As such, the passion is rekindled to exploit the role of TME in ovarian cancer progression and metastasis for discovery of novel therapeutics for this deadly disease. In the current review, we revisit the recent mechanistic insights into the contributions of TME to the development, progression, prognosis prediction and therapeutic efficacy of ovarian cancer via modulating cancer hallmarks. We also explored potentially promising predictive and prognostic biomarkers for ovarian cancer patients.

中文翻译：

---

针对卵巢癌中的肿瘤微环境：前提和承诺。

卵巢癌是全球妇科癌症相关死亡率的主要原因。多数卵巢癌患者在标准治疗方法后均复发，并且由于耐药性，癌症治疗的临床获益并不令人满意。靶向肿瘤微环境（TME）成分的某些新型药物已被美国食品和药物管理局批准用于实体癌。因此，重新燃起了对TME在卵巢癌进展和转移中的作用的热情，以发现这种致命疾病的新疗法。在当前的审查中，我们通过调节癌症标志物，回顾有关TME对卵巢癌的发展，进展，预后预测和治疗功效的贡献的最新机制。